Fortis Healthcare has launched a new medical institute dedicated to genomic medicine, aiming to enhance personalized and gene-targeted healthcare for complex diseases such as cancer, heart disorders, and neurological conditions.
The Fortis Institute of Genomic Medicine, unveiled on Tuesday, will use advanced genetic testing to improve diagnosis, early detection, and treatment precision. According to the hospital, the initiative brings together specialists from oncology, cardiology, neurology, pathology, and genomics under one umbrella to decode genetic markers and deliver tailored care.
Focusing on onco-genomics, cardio-genomics, and neuro-genomics, the institute will apply cutting-edge research to offer customized treatments for patients with aggressive cancers, congenital heart diseases, and rare neurological conditions.
“This approach will not only allow for earlier detection and risk assessment but also greatly improve treatment accuracy in complex medical cases,” said Anil Vinayak, Group Chief Operating Officer at Fortis Healthcare. “By integrating genomics into our core offerings, we are reshaping the future of healthcare with data-driven, personalized care.”
Speaking at the launch event held at Fortis Memorial Research Institute (FMRI), Gurugram, Facility Director Yash Rawat emphasized the importance of genomics in managing India’s rising burden of non-communicable diseases.
“Whether it’s a child with unexplained anemia or a woman with a family history of breast cancer, genomics enables more precise treatment strategies, better outcomes, and risk reduction,” Rawat said.
Fortis noted that through genomics, doctors will be better equipped to understand genetic conditions, offer more accurate therapies, and ensure early diagnosis—especially for patients with inherited or rare disorders.
